Inquiry Basket
Loading ......
25-hydroxyvitamin D (25-OH vitamin D or 25(OH)D) is the primary biomarker used to evaluate vitamin D status. Vitamin D is best known for maintaining calcium balance and supporting bone mineralization, but its biological effects extend well beyond the skeletal system. Through the vitamin D receptor (VDR), vitamin D signaling participates in immune regulation, cellular differentiation, endocrine function, muscle physiology, and metabolic homeostasis. When low 25(OH)D status persists for a prolonged period, its effects may therefore extend across multiple organ systems.
The most clearly established consequences of long-term 25-OH vitamin D deficiency involve the bones and muscles. Severe or persistent deficiency can impair calcium and phosphate absorption and interfere with normal bone mineralization, resulting in rickets in children and osteomalacia in adults. These conditions can produce bone pain, skeletal deformities, impaired physical function, and increased susceptibility to fractures. Chronic vitamin D deficiency may also stimulate parathyroid hormone secretion, leading to secondary hyperparathyroidism. Although this response helps maintain circulating calcium concentrations, persistent elevation of parathyroid hormone can increase bone turnover and further compromise skeletal integrity. Vitamin D deficiency can also affect skeletal muscle. Inadequate vitamin D signaling may be associated with muscle weakness, impaired physical performance, muscle discomfort, and myopathy, particularly in people with severe deficiency. Reduced muscle strength combined with impaired balance can increase the likelihood of falls, making vitamin D status particularly relevant to bone health in older adults and other populations already vulnerable to fractures.
Vitamin D also acts as an important immune regulator. VDR-mediated signaling occurs in several immune cell populations, where vitamin D can influence innate immune responses, antigen presentation, T-cell activity, and B-cell function. This broad immunomodulatory role has led researchers to investigate whether long-term vitamin D deficiency contributes to abnormal immune activation and autoimmune disease. Lower 25(OH)D concentrations have been associated with an increased risk of several autoimmune and inflammatory disorders, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. Vitamin D signaling may help maintain immune tolerance and regulate excessive inflammatory responses, providing a plausible biological explanation for these associations. However, the relationship is complex, and low vitamin D status may also arise as a consequence of chronic disease, reduced mobility, altered nutrition, or other factors. Vitamin D should therefore be considered one component of immune health rather than a standalone explanation for autoimmune disease.
Long-term low vitamin D status has also been linked to a range of cardiovascular and metabolic conditions. Epidemiological research has repeatedly observed associations between low 25(OH)D concentrations and hypertension, cardiovascular disease, insulin resistance, and diabetes. Vitamin D signaling is present in cardiovascular tissues and pancreatic endocrine cells, suggesting that the vitamin D endocrine system may influence vascular function, inflammatory signaling, glucose metabolism, and pancreatic physiology. Both type 1 and type 2 diabetes have been investigated in relation to vitamin D status. Vitamin D may influence immune pathways involved in pancreatic beta-cell function and type 1 diabetes, while its potential effects on insulin sensitivity and metabolic regulation have generated substantial interest in type 2 diabetes. Nevertheless, these relationships should not be interpreted as proof that vitamin D deficiency directly causes diabetes or cardiovascular disease. Obesity, physical inactivity, chronic inflammation, kidney function, diet, and other metabolic factors can simultaneously influence both vitamin D status and disease risk.
The potential relationship between vitamin D deficiency and cancer has attracted extensive scientific interest. Vitamin D signaling through VDR can affect biological processes relevant to cancer development, including cellular differentiation, proliferation, apoptosis, inflammation, and tissue homeostasis. Because these pathways are closely connected to the control of abnormal cell growth, vitamin D has been investigated as a potential factor in cancer prevention and progression.
Low vitamin D status has been associated with an increased risk of several cancers in observational studies. However, cancer is a highly heterogeneous group of diseases, and vitamin D status is influenced by many variables that can also affect cancer risk. Consequently, although vitamin D signaling has compelling biological relevance to cancer biology, current evidence does not justify treating vitamin D deficiency as a direct or universal cause of cancer. Vitamin D status should instead be viewed as one potentially relevant factor within a much larger network of genetic, environmental, metabolic, and lifestyle influences.
The broad biological effects of vitamin D are largely explained by the distribution and function of the vitamin D receptor (VDR). VDR is expressed in a wide range of cell types, allowing vitamin D signaling to influence tissues far beyond those directly involved in calcium metabolism. The vitamin D endocrine system is involved in the regulation of genes associated with cellular differentiation, cell-cycle control, immune activity, and tissue-specific cellular functions. Through these mechanisms, vitamin D signaling can participate in physiological processes in the immune system, cardiovascular system, pancreas, skeletal muscle, adipose tissue, and other organs. This is why vitamin D is increasingly understood as a pleiotropic hormone-like regulator rather than simply a nutrient required for healthy bones. When 25(OH)D availability remains low for an extended period, vitamin D-dependent signaling pathways may be altered across several tissues, although the clinical importance of these changes varies between individuals and disease states.
One of the most important considerations when discussing the systemic consequences of vitamin D deficiency is the difference between biological association and proven causation. Numerous observational studies have reported that people with lower 25(OH)D concentrations are more likely to have cardiovascular disease, diabetes, autoimmune disorders, cancer, or other chronic conditions. These findings are scientifically important, but they do not automatically demonstrate that vitamin D deficiency caused those diseases. The relationship can work in both directions. Chronic illness may reduce outdoor activity, alter dietary intake, affect vitamin D metabolism, or increase physiological demands, thereby lowering circulating 25(OH)D levels. Other factors, such as age, obesity, kidney or liver function, physical activity, and overall health status, can also influence both vitamin D concentrations and disease risk. Randomized clinical trials have therefore produced more nuanced results than observational studies, with benefits not consistently demonstrated across all non-skeletal outcomes.
The strongest evidence for vitamin D deficiency remains its impact on bone mineralization, calcium homeostasis, muscle function, and fracture-related health. At the same time, the extensive distribution of VDR and the diverse functions of vitamin D signaling provide a strong biological basis for investigating its potential role in immune, cardiovascular, metabolic, and cellular processes. For this reason, persistent 25-OH vitamin D deficiency deserves attention as more than an isolated nutritional finding. Assessing 25(OH)D can help identify inadequate vitamin D status, particularly in individuals with recognized risk factors for deficiency. However, interpreting the result requires consideration of the broader clinical context. The evidence linking vitamin D deficiency to many systemic diseases remains an active area of research, and association should not be presented as established causation. A scientifically responsible understanding of vitamin D therefore combines its well-established skeletal functions with a careful interpretation of emerging evidence regarding its broader systemic effects.
Long-term 25-OH vitamin D deficiency most clearly affects bone and muscle health, potentially causing impaired bone mineralization, osteomalacia, secondary hyperparathyroidism, muscle weakness, and increased fracture or fall risk. Low vitamin D status has also been associated with immune, cardiovascular, metabolic, and other systemic conditions, although many of these relationships remain under investigation.
Yes. Vitamin D signaling through the vitamin D receptor (VDR) contributes to the regulation of innate and adaptive immune responses. Persistently low 25(OH)D levels have been associated with several autoimmune and inflammatory conditions, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. However, low vitamin D status does not necessarily mean that deficiency directly causes these diseases.
Low 25(OH)D levels are associated with diabetes, hypertension, and cardiovascular disease in many observational studies. Vitamin D signaling may influence pancreatic endocrine function, glucose metabolism, vascular biology, and inflammation. However, factors such as obesity, physical inactivity, chronic disease, and kidney function can affect both vitamin D status and metabolic health, so a direct causal relationship has not been established for all of these conditions.
Low vitamin D status has been associated with several types of cancer, and VDR signaling can influence cellular differentiation, proliferation, apoptosis, and inflammatory pathways. Nevertheless, current evidence does not establish long-term vitamin D deficiency as a direct cause of cancer. Vitamin D is one potential biological factor among many determinants of cancer risk.
Long-term vitamin D status is primarily assessed by measuring serum 25-hydroxyvitamin D [25(OH)D]. The result should be interpreted according to the laboratory's reference range and the individual's health status, diet, sun exposure, medications, and other risk factors. When deficiency is suspected or being monitored, clinical interpretation is more informative than relying on symptoms alone.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
